Motus GI
MOTSPrivate Company
Total funding raised: $52M
Overview
Motus GI is a medical device company with a mission to improve clinical outcomes and cost-efficiency in GI endoscopy through its innovative Pure-Vu® System. The company has achieved key regulatory milestones, including FDA clearance and CE Mark, and has transitioned to commercial operations, targeting the significant inpatient and emergent endoscopy market. Its strategy centers on direct engagement with early-adopter hospitals and endoscopy centers, leveraging compelling clinical data that demonstrates dramatic improvements in procedural visualization and success rates.
Technology Platform
The Pure-Vu® System is a single-use medical device that integrates with standard endoscopes to provide simultaneous high-flow irrigation and suction, actively cleansing the GI tract during endoscopy to improve visualization.
Funding History
5Opportunities
Risk Factors
Competitive Landscape
Primary competition is the inefficient standard of care using the endoscope's own channels. The Pure-Vu System holds a first-mover advantage with specific FDA clearance and strong clinical data, but faces potential competition from other cleansing devices and must overcome entrenched clinical practices.
Competitors
Company Timeline
Founded in Fort Lauderdale, United States
Series B: $15.0M
Series C: $12.0M
IPO — $10.0M